Sapporo Clinical Laboratory Inc. (TYO:9776)
Japan · Delayed Price · Currency is JPY 1,952.00
-8.00 (-0.41%)
Feb 13, 2026, 2:58 PM JST
TYO:9776 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 20,390 | 20,131 | 19,682 | 20,127 | 19,109 | 17,502 | |
Revenue Growth (YoY) | 1.42% | 2.28% | -2.21% | 5.33% | 9.18% | -0.89% |
Cost of Revenue | 14,211 | 13,990 | 13,787 | 13,830 | 12,788 | 11,768 |
Gross Profit | 6,179 | 6,141 | 5,895 | 6,297 | 6,321 | 5,734 |
Selling, General & Admin | 4,625 | 4,606 | 4,549 | 4,483 | 4,070 | 3,901 |
Research & Development | 7 | 7 | 9 | 9 | 10 | 8 |
Other Operating Expenses | 633 | 633 | 628 | 625 | 559 | 570 |
Operating Expenses | 5,454 | 5,435 | 5,360 | 5,284 | 4,784 | 4,592 |
Operating Income | 725 | 706 | 535 | 1,013 | 1,537 | 1,142 |
Interest Expense | -5 | -6 | -7 | -8 | -9 | -2 |
Interest & Investment Income | 13 | 6 | 5 | 5 | 6 | 5 |
Other Non Operating Income (Expenses) | - | 1 | -19 | 147 | 69 | 42 |
EBT Excluding Unusual Items | 733 | 707 | 514 | 1,157 | 1,603 | 1,187 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -11 |
Gain (Loss) on Sale of Assets | - | 1 | -5 | - | 1 | - |
Asset Writedown | -9 | -8 | -58 | -199 | -28 | - |
Other Unusual Items | -129 | -1 | 146 | - | -76 | -1 |
Pretax Income | 595 | 699 | 597 | 958 | 1,500 | 1,175 |
Income Tax Expense | 211 | 241 | 234 | 319 | 455 | 382 |
Earnings From Continuing Operations | 384 | 458 | 363 | 639 | 1,045 | 793 |
Minority Interest in Earnings | 2 | 6 | 17 | -71 | -3 | - |
Net Income | 386 | 464 | 380 | 568 | 1,042 | 793 |
Net Income to Common | 386 | 464 | 380 | 568 | 1,042 | 793 |
Net Income Growth | -11.47% | 22.11% | -33.10% | -45.49% | 31.40% | 50.19% |
Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | 3 |
Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | 3 |
Shares Change (YoY) | -1.97% | -6.07% | -0.12% | -2.11% | -0.50% | - |
EPS (Basic) | 123.77 | 148.34 | 114.11 | 170.37 | 305.93 | 231.67 |
EPS (Diluted) | 123.77 | 148.34 | 114.11 | 170.37 | 305.93 | 231.67 |
EPS Growth | -9.69% | 29.99% | -33.02% | -44.31% | 32.06% | 50.19% |
Free Cash Flow | - | -492 | 689 | 619 | 736 | -2,305 |
Free Cash Flow Per Share | - | -157.29 | 206.91 | 185.66 | 216.09 | -673.39 |
Dividend Per Share | 23.000 | 23.000 | 23.000 | 23.000 | 23.000 | 23.000 |
Dividend Growth | - | - | - | - | - | 130.00% |
Gross Margin | 30.30% | 30.50% | 29.95% | 31.29% | 33.08% | 32.76% |
Operating Margin | 3.56% | 3.51% | 2.72% | 5.03% | 8.04% | 6.53% |
Profit Margin | 1.89% | 2.31% | 1.93% | 2.82% | 5.45% | 4.53% |
Free Cash Flow Margin | - | -2.44% | 3.50% | 3.08% | 3.85% | -13.17% |
EBITDA | 1,300 | 1,264 | 1,070 | 1,532 | 2,084 | 1,413 |
EBITDA Margin | 6.38% | 6.28% | 5.44% | 7.61% | 10.91% | 8.07% |
D&A For EBITDA | 575.25 | 558 | 535 | 519 | 547 | 271 |
EBIT | 725 | 706 | 535 | 1,013 | 1,537 | 1,142 |
EBIT Margin | 3.56% | 3.51% | 2.72% | 5.03% | 8.04% | 6.53% |
Effective Tax Rate | 35.46% | 34.48% | 39.20% | 33.30% | 30.33% | 32.51% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.